P+P advises Equistone on the sale of CU Chemie UETIKON Group
Funds managed by Equistone Partners Europe have sold their majority shareholding in CU CHEMIE UETIKON to the French pharmaceuticals and chemicals company Novacap.
Equistone had acquired a majority shareholding in Uetikon as part of a management buy-out in November 2011 and has now concluded the exit. The parties agreed not to disclose the selling price. The transaction is still subject to approval by the antitrust authorities.
The Uetikon Group, with its registered office in Lahr, Baden-Württemberg, manufactures specialized fine chemicals and pharmaceutical ingredients and specializes in the custom synthesis of complex multi-step intermediates and pharmaceutical substances. The company provides services to leading pharmaceutical companies across the globe.
P+P comprehensively advised on the transaction, including antitrust, financing and tax aspects, with an interdisciplinary team in all of our locations:
- Dr. Ralf Bergjan (lead, M&A, Munich)
- Adam Denes (associate, M&A, Berlin)
- Daniel Wiedmann (counsel, antitrust law, Frankfurt)
- Dr. Jens Linde (counsel, finance, Frankfurt)
- Michael Schuhmacher (associate, finance, Frankfurt)
- Dr. Nico Fischer (counsel, tax, Munich)
On the seller's side, Ashurst served as advisors for the Novacap International SAS Group under the leadership of Fabian von Samson-Himmelstjerna (M&A), Ute Zinsmeister, Maria Held (antitrust law), Heiko Penndorf and Felix Krüger (tax).
